Arrowhead Pharmaceuticals Commences P-I/IIa Trial of ARO-INHBE to Treat Obesity
Shots:
- Arrowhead has dosed the first patients with ARO-INHBE (RNAi therapy) in P-I/IIa clinical evaluation for treating obesity. The company has also submitted application to conduct human trial of ARO-ALK7 in obesity
- The dose-escalating P-I/IIa (AROINHBE-1001) study will assess safety, tolerability & PK/PD of ARO-INHBE among obese adults (n=78) in 2 parts, with part 1 evaluating single & multiple doses of ARO-INHBE alone while part 2 evaluating ARO-INHBE + tirzepatide
- ARO-INHBE targets INHBE gene to reduce Activin E, improving fat distribution and metabolic health. Its preclinical results depicted reduced weight & fat while preserving lean muscle mass, offering a novel obesity treatment mechanism
Ref: Arrowhead Pharmaceuticals | Image: Arrowhead Pharmaceuticals
Related News:- Arrowhead Pharmaceuticals Reports the P-III (PALISADE) Trial Results of Plozasiran to Treat Familial Chylomicronemia Syndrome (FCS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
